OSLO, March 5 (Reuters) - Novo Nordisk's

widely used diabetes drug Ozempic delayed progression of chronic

kidney disease in diabetes patients, according to a large

late-stage study.

"The trial achieved its primary endpoint by

demonstrating a statistically significant and superior reduction

in kidney disease progression, major adverse cardiovascular

events (MACE) and death of 24%," it said in a statement.